Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …

To identify approaches to target DNA repair vulnerabilities in cancer, we discovered
nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …

Abstract 53BP1 is a chromatin-binding protein that regulates the repair of DNA double-
strand breaks by suppressing the nucleolytic resection of DNA termini,. This function of …

PARP inhibitors (PARPi), a cancer therapy targeting poly (ADP-ribose) polymerase, are the
first clinically approved drugs designed to exploit synthetic lethality, a genetic concept …